What this pack is
Forlax is the brand name in this record; macrogol 4000 is the generic name. Read both together with the dosage form (exact dosage form to be checked from the current pack).
PACK CHECK · MARKET FIRST
ForlaxGeneric namemacrogol 4000
Mainland China pack-name cue福松®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
This osmotic laxative increases water in stools to help constipation.
Read source: Singapore ↗reviewed 2026-09-09More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 福松®
- International brand name
- Forlax
- Source-scoped market brand names
- FORLAX 10 g · FranceSource-scoped evidence ↗Named reference product in French group 736.
- FORLAX · SingaporeSource-scoped evidence ↗SIN12419P; 10 g/sachet.
- 福松® · Mainland China: historical name cueSource-scoped evidence ↗Ipsen release from 2020; not current authorisation, reimbursement or stock evidence.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- macrogol 4000
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
Mainland China trade-name search cue:福松®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
FR · French leaflet 20 February 2026
10 g macrogol 4000 per sachet; 10.167 g total powder; 20 sachets/carton
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- 3400933899783
- Form and route
- Powder for oral solution · Oral
- Listing review
- Cited product evidence reviewed 2026-09-09; actual marketing, stock and availability are not established.
- macrogol 4000
- 10 gActive amount per sachet
- Package
- 20 sachets/carton
PACKAGE-VISUAL STATUS
Exact official pack photograph still needed
Other strengths or retail pictures do not stand in for a Chinese pack; this French text card cannot authenticate a medicine.
LABEL READING · NOT A PRESCRIPTION
Large-print French leaflet: strength and older-person checks
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
Separate active amount, total powder mass and pack count. These points refer to the French original.
- 10 g is active amount per sachet; 10.167 g includes excipients; 20 is pack count. Check your prescription and local leaflet for your dose.
- Diarrhoea needs attention to fluid and electrolyte loss, particularly in older people or those with kidney/liver problems or diuretic use.
- Other oral medicines may be absorbed less well temporarily. Ask a pharmacist to review the full list; spacing alone does not establish safety.
- Do not self-treat suspected obstruction, perforation or unexplained abdominal pain; breathing difficulty or face/throat swelling needs emergency help.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkANSM · France · Government medicines database and public leaflet · 2026-09-09
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- France · 1
- See original document · 1
- Singapore · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFrance public medicines database / ANSM: FORLAX 10 g, CIS 69298346; leaflet updated 2026-02-20 ↗reviewed 2026-09-09
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- Public product-record source · See original document · Public product record · 2026-09-09France public medicines database: macrogol 4000 10 g reference group 736; updated 2026-08-31 ↗reviewed 2026-09-09
- Singapore National Drug Formulary (NDF) · Singapore · Government drug formulary product information and leaflet excerpts · 2026-09-09Singapore NDF: FORLAX 10 G/SACHET, SIN12419P; updated 2026-07-28 ↗reviewed 2026-09-09
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about Forlax (macrogol 4000). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
Forlax is the brand in this record and macrogol 4000 is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check the exact dosage form
Verify the exact dosage form and current label before altering, transferring or substituting any product. A similar name or previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- France public medicines database / ANSM: FORLAX 10 g, CIS 69298346; leaflet updated 2026-02-20 ↗reviewed 2026-09-09
- France public medicines database: macrogol 4000 10 g reference group 736; updated 2026-08-31 ↗reviewed 2026-09-09
- Singapore NDF: FORLAX 10 G/SACHET, SIN12419P; updated 2026-07-28 ↗reviewed 2026-09-09
HOW IT WORKS · NOT A TREATMENT PLAN
Helps stools retain water; not an instant effect
- The Singapore original describes powder dissolved in water, usually working in 24–48 hours. Do not increase your dose just because it has not worked yet.
- Its local indication covers constipation in adults and children from eight; this 10 g product must not be extrapolated to younger children.
- Singapore limits self-medication to two weeks. Persistent or worsening symptoms need review; severe diarrhoea or vomiting needs prompt care.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- France public medicines database / ANSM: FORLAX 10 g, CIS 69298346; leaflet updated 2026-02-20 ↗reviewed 2026-09-09
- France public medicines database: macrogol 4000 10 g reference group 736; updated 2026-08-31 ↗reviewed 2026-09-09
- Singapore NDF: FORLAX 10 G/SACHET, SIN12419P; updated 2026-07-28 ↗reviewed 2026-09-09
- MHRA Drug Safety Update, 2021-04-27: PEG laxatives and starch-based thickeners, aspiration risk ↗reviewed 2026-09-09
- Ipsen company release via PR Newswire, 2020-08-18: Forlax (macrogol 4000 powder) Chinese brand and partnership history ↗reviewed 2026-09-09
SOURCE-TRACEABLE ARCHIVE
Forlaxmacrogol 4000
This page links to public primary-source material for Forlax. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
French authorisation record
Product-specific French date, not a global first-launch claim for all forms.
France public medicines database / ANSM: FORLAX 10 g, CIS 69298346; leaflet updated 2026-02-20 ↗Chinese brand-history evidence
Ipsen announced a Forlax partnership with Shanghai Pharma.
Ipsen company release via PR Newswire, 2020-08-18: Forlax (macrogol 4000 powder) Chinese brand and partnership history ↗Safety: starch thickeners and aspiration risk
MHRA warns against directly mixing PEG laxatives with starch-thickened liquids: thinning may increase aspiration risk in dysphagia. This is a class warning, not a Forlax recall.
MHRA Drug Safety Update, 2021-04-27: PEG laxatives and starch-based thickeners, aspiration risk ↗
MARKET SCOPE
Market-record boundary
France
Reference group and leaflet checkedThe 20-sachet text record is not live inventory.
Singapore
Government product record checkedHolder DKSH Singapore; local GSL classification does not establish Chinese supply status.
Mainland China
Current authorisation and leaflet unverified福松 is a historical brand cue; no Chinese authorisation number or pack is inferred.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Can a person using swallowing thickeners mix it in?
Ask the pharmacist and swallowing-care team to check the thickener. PEG can thin starch-thickened liquids and increase aspiration risk. Do not improvise mixtures or thickness; see the dated MHRA source above.
Are PEG 3350 and 4000 the same presentation?
Do not identify products by PEG alone. Check the full ingredient, electrolytes, form and local leaflet with a pharmacist.
Does reference status mean other brands cannot be used?
No. The French group also lists generics, with some excipient differences. Identity and excipients alone do not decide a switch for you.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.